HighTower Advisors LLC Grows Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

HighTower Advisors LLC lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.9% during the 4th quarter, Holdings Channel reports. The firm owned 5,683 shares of the medical instruments supplier’s stock after acquiring an additional 212 shares during the period. HighTower Advisors LLC’s holdings in LeMaitre Vascular were worth $524,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. New York State Teachers Retirement System raised its position in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock valued at $755,000 after purchasing an additional 100 shares during the last quarter. Flputnam Investment Management Co. raised its holdings in shares of LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after acquiring an additional 102 shares in the last quarter. Norden Group LLC lifted its stake in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after acquiring an additional 103 shares during the period. Blue Barn Wealth LLC lifted its stake in LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 104 shares during the period. Finally, Shaker Investments LLC OH boosted its holdings in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after acquiring an additional 112 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 1.0 %

LeMaitre Vascular stock opened at $83.05 on Monday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The company has a market capitalization of $1.87 billion, a P/E ratio of 45.38, a PEG ratio of 2.22 and a beta of 0.89. The stock’s 50 day moving average is $93.07 and its 200 day moving average is $94.42.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.96%. LeMaitre Vascular’s payout ratio is 41.24%.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.79% of the company’s stock.

Analyst Ratings Changes

LMAT has been the subject of several research reports. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.